Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma
Haematologica
.
2020 Jan 31;105(2):e72-e75.
doi: 10.3324/haematol.2019.220475.
Print 2020.
Authors
Grzegorz S Nowakowski
1
,
Annalisa Chiappella
2
,
Thomas E Witzig
3
,
David W Scott
4
,
Michele Spina
5
,
Randy D Gascoyne
3
4
,
Lei Zhang
6
,
Jacqueline Russo
6
,
Janet Kang
6
,
Jingshan Zhang
6
,
Yingyong Xu
6
,
Umberto Vitolo
2
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, MN, USA
[email protected]
.
2
Division of Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy.
3
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
4
Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.
5
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy.
6
Celgene Corporation, Summit, NJ; USA.
PMID:
31221781
PMCID:
PMC7012477
DOI:
10.3324/haematol.2019.220475
No abstract available
Publication types
Clinical Trial, Phase III
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Humans
Lymphoma, Large B-Cell, Diffuse*